Skip to main content
. 2016 Jan 18;7(2):225–232. doi: 10.1002/jcsm.12054

Figure 4.

Figure 4

Anti‐cachexia efficacy of salidroside in the combined chemotherapy in LLC models. Like CT‐26 model in combined chemotherapy above, here, LLC models were established again, and the combined chemotherapeutic efficacy of salidroside and DDP was examined with focusing evaluations of anti‐cachexia efficacy of salidroside. Groups were designed like the combined chemotherapy in CT‐26 models. Anti‐cachexia efficacy of salidroside was determined, including (B) tumour growth, (C) body weight, (D) tumour‐free body weight,(E) gastrocnemius muscle, (A) fat mass (bottom, epididymal WAT; top, gonadal WAT), and (F) survival. Results are expressed as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). WAT, white adipose tissue; NS, the control group; DDP, cisplatin.